Internal Medicine, Gastroenterology · New York, NY
NPI
1649364357
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
452 Fort Washington Ave
New York, NY, 10033
Phone (212) 781-8088
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
490 services
Medicare patients, 2024
61
Average age 71
Drug cost, 2024
$952K
5,152 prescriptions
Company payments, 2025
$1,548
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julio E Albarran was code 88305 (surgical pathology examination), 138 times for 32 patients. In total Julio E Albarran billed 490 services in 15 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88305 Surgical Pathology Examination | Office | 138 | 32 | $30.37 | $4,192 |
| 88313 Surgical Pathology Examination | Office | 122 | 31 | $9.91 | $1,209 |
| 88342 Immunohistochemistry | Office | 73 | 20 | $28.84 | $2,105 |
| 99214 Office E&M - Established | Office | 70 | 44 | $91.12 | $6,379 |
| 88312 Surgical Pathology Examination | Office | 20 | 20 | $21.99 | $440 |
| 43239 Upper GI Endoscopy | Facility | 20 | 19 | $93.66 | $1,873 |
| 99204 Office E&M - New | Office | 15 | 15 | $119.02 | $1,785 |
| 45385 Colonoscopy - Lesion Removal | Facility | 11 | 11 | $205.26 | $2,258 |
By year: 2022 $12K for 97 services; 2023 $21K for 433 services; 2024 $22K for 490 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 138 | 32 | $30.37 | $4,192 |
| 88313 Surgical Pathology Examination | 122 | 31 | $9.91 | $1,209 |
| 88342 Immunohistochemistry | 73 | 20 | $28.84 | $2,105 |
| 88312 Surgical Pathology Examination | 20 | 20 | $21.99 | $440 |
Medicare prescription drug claims, 2024
In 2024, the drug Julio E Albarran prescribed most often to Medicare patients was Pantoprazole Sodium, with 1,234 prescriptions and refills. In total Julio E Albarran wrote 5,152 Medicare prescriptions that cost $952K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 1,234 | 2,804 | 489 | $10K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 660 | 660 | 633 | $8,475 |
| Famotidine Generic | 481 | 1,202 | 203 | $3,965 |
| Linzess Linaclotide | 454 | 698 | 136 | $351K |
| Sucralfate Generic | 209 | 278 | 66 | $4,468 |
| Paroxetine Hcl Generic | 148 | 211 | 51 | $762 |
| Trulance Plecanatide | 132 | 201 | 53 | $105K |
| Procto-Med Hc Hydrocortisone | 101 | 101 | 38 | $668 |
| Omeprazole Generic | 100 | 211 | 53 | $1,266 |
| Lansoprazole Generic | 79 | 172 | 34 | $559 |
| Dicyclomine Hcl Generic | 72 | 76 | 47 | $172 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 70 | 70 | 67 | $835 |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 57 | 57 | 54 | $779 |
| Hydrocortisone Generic | 52 | 52 | 24 | $427 |
| Dexlansoprazole Dr Dexlansoprazole | 51 | 112 | 21 | $13K |
Brand drugs: - claims; generic drugs: 4,113 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Julio E Albarran $1,548 ($1,548 in general payments such as food, travel and fees) from 8 companies. The largest payer was Phathom Pharmaceuticals, Inc. with $540.
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. PHAT | 10 | $540 |
| Madrigal Pharmaceuticals MDGL | 20 | $413 |
| Ardelyx, Inc. ARDX | 11 | $268 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 10 | $167 |
| Abbvie Inc. ABBV | 3 | $62.88 |
| Aimmune Therapeutics, Inc. | 2 | $49.14 |
| Gilead Sciences, Inc. GILD | 1 | $27.43 |
| Novo Nordisk Inc NVO | 1 | $20.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.